Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) is advancing the development of its lead oncology candidate, ONC010, a PNKP inhibitor designed to disrupt cancer cells’ DNA repair mechanisms and potentially address treatment resistance. The company recently achieved a milestone by advancing kilogram-scale manufacturing of a key precursor used to produce ONC010’s active pharmaceutical ingredient, supporting future formulation development, GMP production and clinical studies.
In addition to manufacturing progress, Onco-Innovations signed a letter of intent with Nanosoft Polymers to advance polymer development, drug delivery optimization and formulation work. Engagements with Nucro-Technics and Avance Clinical support bioanalytical development and clinical and regulatory planning. These collaborative efforts reflect the company’s broader strategy to build the manufacturing, formulation and clinical infrastructure needed to advance ONC010 toward future first-in-human studies.
The significance of this announcement lies in the potential of ONC010 to overcome treatment resistance, a major challenge in oncology. By inhibiting PNKP, the drug targets a key enzyme in DNA repair, making cancer cells more susceptible to DNA-damaging therapies such as radiation and chemotherapy. If successful, ONC010 could offer new options for patients with solid tumors that have become resistant to existing treatments.
Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. The company’s mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. It has secured an exclusive worldwide license to patented technology that targets solid tumors. For more information, visit the company’s website at https://oncoinnovations.com.
The latest news and updates relating to ONNVF are available in the company’s newsroom at https://ibn.fm/ONNVF.
